BMO cuts Novo Nordisk stock price target on Ozempic headwinds
BMO Capital reduced its price target for Novo Nordisk (NYSE: NVO) to $40 from $47, citing challenges in Ozempic revenue due to market share decline and tough year-over-year comparisons. The stock is down 21.5% year-to-date. Novo Nordisk recently entered a licensing deal with Nanexa and plans a potential NYSE listing. Morgan Stanley downgraded the stock to Underweight.
How this was made
The 30-second read
Why it matters
The immediate trading signal is the PT cut tied to Ozempic headwinds, which can influence positioning ahead of upcoming earnings and any further analyst revisions.
Market read
A large-cap GLP-1 name faces renewed near-term revenue skepticism as an analyst PT is cut on Ozempic-specific headwinds.
What to watch
The piece also mentions licensing deals and potential NYSE listing considerations, which could support longer-term optionality even if near-term Ozempic comparisons look pressured.
Background
The article frames BMO’s downgrade of expectations around Ozempic’s U.S. revenue trajectory and the impact of prior gross-to-net adjustments.
Ticker impact
BMO cut Novo Nordisk’s price target to $40 from $47, citing Ozempic headwinds from tougher comparisons and declining U.S. share.
Likely downward pressure or capped upside as traders price in weaker Ozempic revenue assumptions tied to U.S. share and comparisons.
The article’s actionable catalyst is the PT reduction with a specific Ozempic-focused thesis (declining U.S. market share and tougher YoY comparisons). It also notes a gross-to-net adjustment that may distort YoY comparisons, which can affect near-term expectations.
Market effects
Adds incremental caution to GLP-1 obesity/diabetes names by highlighting U.S. share and gross-to-net comparison distortions.
Limited, mostly U.S. healthcare sentiment via a large-cap European pharma ADR.
Moderate, as Ozempic demand and competitive dynamics are globally watched for GLP-1 supply chain and pricing expectations.
Counterpoint
The gross-to-net adjustment may exaggerate YoY declines, and the article suggests the stock could be undervalued at current levels, implying limited downside if fundamentals hold.
Key entities
- companyNovo Nordisk
Subject of the article, with BMO lowering its price target due to Ozempic headwinds and U.S. share pressure.
- analyst_firmBMO Capital
Issued the updated price target and maintained a Market Perform rating.
- companyNanexa
Swedish biotech referenced for a licensing agreement using PharmaShell technology.
- companyHengrui
Referenced as the source of HRS-1596 licensing plans.
- analyst_firmMorgan Stanley
Referenced as having downgraded Novo Nordisk to Underweight on growth and patent-expiration risks.
